Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals Inc (IMLFF)

Inmed Pharmaceuticals Inc (IMLFF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
InMed Releases CBN Preclinical Results in Glaucoma

, /PRNewswire/ -  ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 0.2406 (+3.93%)
InMed Releases CBN Preclinical Results in Glaucoma

VANCOUVER , May 27, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

, /PRNewswire/ - ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in...

IMLFF : 0.2406 (+3.93%)
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

VANCOUVER , May 19, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 0.2406 (+3.93%)
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER , May 14, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed Files PCT Patent Application for Neuroprotection in Glaucoma

, /PRNewswire/ - ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in...

IMLFF : 0.2406 (+3.93%)
InMed Files PCT Patent Application for Neuroprotection in Glaucoma

VANCOUVER , May 12, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

, /PRNewswire/ - ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in...

IMLFF : 0.2406 (+3.93%)
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

VANCOUVER , May 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 0.2406 (+3.93%)
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference

VANCOUVER , May 7, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed and Almac Group Developing Improved Cannabinoid Production Methods

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.2406 (+3.93%)
InMed and Almac Group Developing Improved Cannabinoid Production Methods

VANCOUVER , May 5, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IN.TO : 0.34 (+9.68%)
IMLFF : 0.2406 (+3.93%)
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

, /PRNewswire/ - ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way...

IMLFF : 0.2406 (+3.93%)
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

VANCOUVER , April 30, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IN.TO : 0.34 (+9.68%)
IMLFF : 0.2406 (+3.93%)
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.2406 (+3.93%)
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER , April 1, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the...

IMLFF : 0.2406 (+3.93%)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

VANCOUVER , March 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.2406 (+3.93%)
IN.TO : 0.34 (+9.68%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -2.57 , SEDG -1.95 , THC -0.82 , TER -3.03 , LITE -1.54
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar